PDE3A-SLCO1C1 Locus is Associated with Response to Anti-Tumor Necrosis Factor Therapy in Psoriatic Arthritis

References

• Gladman DD . Future trends in research in psoriatic arthritis . J. Rheumatol. Suppl.89 , 106 – 110 ( 2012 ).
   PubMedGoogle Scholar
• Taylor W , GladmanD , HelliwellP , MarchesoniA , MeaseP , MielantsH . Classification criteria for psoriatic arthritis: development of new criteria from a large international study . Arthritis Rheum.54 ( 8 ), 2665 – 2673 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ibrahim G , WaxmanR , HelliwellP S . The prevalence of psoriatic arthritis in people with psoriasis . Arthritis Rheum.61 ( 10 ), 1373 – 1378 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Julia A , TortosaR , HernanzJMet al. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes . Hum. Mol. Genet.21 ( 20 ), 4549 – 4557 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kristensen LE , EnglundM , NeoviusM , AsklingJ , JacobssonLT , PeterssonI F . Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study . Ann. Rheum. Dis.72 ( 10 ), 1675 – 1679 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gossec L , SmolenJS , Gaujoux-VialaCet al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies . Ann. Rheum. Dis.71 ( 1 ), 4 – 12 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Saad AA , AshcroftDM , WatsonKD , SymmonsDP , NoycePR , HyrichK L . Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register . Rheumatology49 ( 4 ), 697 – 705 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kristensen LE , GulfeA , SaxneT , GeborekP . Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register . Ann. Rheum. Dis.67 ( 3 ), 364 – 369 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Van Den Bosch F , MangerB , GoupillePet al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions . Ann. Rheum. Dis.69 ( 2 ), 394 – 399 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Villanova F , Di MeglioP , NestleFO . Biomarkers in psoriasis and psoriatic arthritis . Ann. Rheum. Dis.72 ( Suppl. 2 ), ii104 – ii110 ( 2013 ).
   PubMedGoogle Scholar
• O’Rielly DD , RahmanP . Genetics of susceptibility and treatment response in psoriatic arthritis . Nat. Rev. Rheumatol.7 ( 12 ), 718 – 732 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Prieto-Perez R , CabaleiroT , DaudenE , Abad-SantosF . Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases . Pharmacogenomics J.13 ( 4 ), 297 – 305 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Feldmann M . Development of anti-TNF therapy for rheumatoid arthritis . Nat. Rev. Immunol.2 ( 5 ), 364 – 371 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Smolen JS , HanC , BalaMet al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study . Arthritis Rheum.52 ( 4 ), 1020 – 1030 ( 2005 ).
   PubMedGoogle Scholar
• Acosta-Colman I , PalauN , TorneroJet al. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis . Pharmacogenomics14 ( 7 ), 727 – 734 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Ellinghaus E , StuartPE , EllinghausDet al. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL . J. Invest. Dermatol.132 ( 4 ), 1133 – 1140 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Van Der Linden S , ValkenburgHA , CatsA . Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria . Arthritis Rheum.27 ( 4 ), 361 – 368 ( 1984 ).
   PubMed Web of Science ®Google Scholar
• Wagner CL , VisvanathanS , ElashoffMet al. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab . Ann. Rheum. Dis.72 ( 1 ), 83 – 88 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cui J , SaevarsdottirS , ThomsonBet al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy . Arthritis Rheum.62 ( 7 ), 1849 – 1861 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Murdaca G , GulliR , SpanoFet al. TNF-alpha gene polymorphisms: association with disease susceptibility and response to anti-TNF-alpha treatment in psoriatic arthritis . J. Invest. Dermatol. doi:10.1038/jid.2014.123 ( 2014 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Gauderman WJ , MorrisonJ M . QUANTO 1.1: a computer program for power and sample size calculations for genetic-epidemiology studies ( 2006 ). http://hydra.usc.edu/gxe .
   Google Scholar
• Fransen J , Van RielP L . The Disease Activity Score and the EULAR response criteria . Rheum. Dis. Clin. North Am.35 ( 4 ), 745 – 757 , vii–viii ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Krintel SB , PalermoG , JohansenJSet al. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis . Pharmacogenet. Genomics22 ( 8 ), 577 – 589 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Plant D , BowesJ , PotterCet al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci . Arthritis Rheum.63 ( 3 ), 645 – 653 ( 2011 ).
   PubMedGoogle Scholar
• R statistical software version 3.0.1 . www.R-project.org .
   Google Scholar
• Maurice DH , KeH , AhmadF , WangY , ChungJ , ManganielloVC . Advances in targeting cyclic nucleotide phosphodiesterases . Nat. Rev. Drug Discov.13 ( 4 ), 290 – 314 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kavanaugh A , MeasePJ , Gomez-ReinoJJet al. Treatment of psoriatic arthritis in a Phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor . Ann. Rheum. Dis.73 ( 6 ), 1020 – 1026 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Wittmann M , HelliwellP S . Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases . Dermatol. Ther.3 ( 1 ), 1 – 15 ( 2013 ).
   PubMedGoogle Scholar
• Wada T , OnogiY , KimuraYet al. Cilostazol ameliorates systemic insulin resistance in diabetic db/db mice by suppressing chronic inflammation in adipose tissue via modulation of both adipocyte and macrophage functions . Eur. J. Pharmacol.707 ( 1–3 ), 120 – 129 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Park SY , LeeSW , BaekSHet al. Suppression of PU.1-linked TLR4 expression by cilostazol with decrease of cytokine production in macrophages from patients with rheumatoid arthritis . Br. J. Pharmacol.168 ( 6 ), 1401 – 1411 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Yiannakopoulou E . Pharmacogenomics of phase II metabolizing enzymes and drug transporters: clinical implications . Pharmacogenomics J.13 ( 2 ), 105 – 109 ( 2013 ).
   PubMed Web of Science ®Google Scholar